From Nasdaq: 2025-06-21 18:10:00

Biotech stocks offer potential for growth, with two candidates showing forecasts for over 80% and 200% gains in the next 12 months. Viking Therapeutics (VKTX) is advancing weight loss drug VK2735, with phase 3 trials and pill version data expected. CRISPR Therapeutics (CRSP) saw a surge after its gene-editing product approval, but offers a good buying opportunity now. Positive phase 1 data for high cholesterol and upcoming trial updates make CRISPR a promising investment, with an 84% gain forecasted by Wall Street. Investors can capitalize on these opportunities for significant returns in the future.



Read more at Nasdaq: 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts